-
Share
99 Posts.
7
15/11/17
17:40
Share
same as all the medical cannabis names aiming to deliver pharmaceutical grade products, predominantly to europe
while this takes time, earning income from vetinary products that require less approcals - that is happening now
added a canadian production facility - could be worth significant upgrade as it comes on
run by a hard nosed swiss female CEO who is driven to deliver
current market cap after all issues and escrow shares circa 90 mill / about half that of the ones with crops in production
does have partner with import approvals
was issue earlier this year at 68c and ipo at 20c
will be 1.00 before year end if it just keeps delivering milestones and especially with vet products now on the market
-